Anugerah 88 Logo
$42.38+0.20|(+0.47%)
52W H: 59.6852W L: 40.51Beta: 0.53

About Supernus Pharmaceuticals Inc

Frequently Asked Questions

What is the 52-week range for SUPN?

The 52-week high is $59.68 and the 52-week low is $40.51.

What is the P/E ratio for SUPN?

The P/E ratio data is currently unavailable.

What is the dividend yield for SUPN?

This company does not currently pay a dividend or the data is unavailable.

What is the Return on Equity (ROE)?

The trailing twelve months (TTM) Return on Equity is -10.42%.

What is the Net Profit Margin?

The Net Profit Margin (TTM) is -13.23%.

What is the Price to Book (P/B) Ratio?

The annual Price to Book ratio stands at 2.68.

Analyst Recommendation Trends

Wall Street analyst consensus for SUPN over the last few months:

2026-09-01
Buy: 6
S.Buy: 3
Hold: 2
Sell: 0
2026-08-01
Buy: 6
S.Buy: 4
Hold: 2
Sell: 0
2026-07-01
Buy: 6
S.Buy: 4
Hold: 2
Sell: 0
2026-06-01
Buy: 6
S.Buy: 4
Hold: 2
Sell: 0

Latest SUPN News

1 Unprofitable Stock with Impressive Fundamentals and 2 We Avoid

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.

Yahoo9/30/2026

Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?

BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.

Yahoo9/28/2026

2 Growth Stocks to Add to Your Roster and 1 We Question

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Yahoo9/28/2026

Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its 2026 Half-Year and Second Quarter financial results and provided a corporate update. “The successful raising of USD 2.8 million during the last quarter enables us to continue advancing our in-house GABA

Yahoo9/28/2026

Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders, today announced that it has regained full global rights to all GABAB positive allosteric modulator (PAM) assets discovered under its research collaboration with Indivior UK Limited (“Indivior”). The return of the rights follows Indivior’s ra

Yahoo9/25/2026

3 Reasons SUPN is Risky and 1 Stock to Buy Instead

Over the last six months, Supernus Pharmaceuticals’s shares have sunk to $41.99, producing a disappointing 14.7% loss - a stark contrast to the S&P 500’s 16.4% gain. This may have investors wondering how to approach the situation.

Yahoo9/21/2026

Why Did Supernus Pharmaceuticals (SUPN) Move Today?

Supernus Pharmaceuticals (SUPN) is back in focus after reporting Q2 revenue of US$211.3 million, up 27.7% year on year, beating expectations and nudging full-year guidance higher on what management described as sustained product momentum. The upbeat quarter comes amid a more challenging period for Supernus Pharmaceuticals, with the share price down 15.1% year to date and about 13.5% lower over the past month, even though the 3-year total shareholder return of roughly 49% still points to a...

Yahoo9/19/2026

How Supernus’ Q2 Beat and Raised Guidance Could Reshape Supernus Pharmaceuticals (SUPN) Investors’ Outlook

In Q2 2026, Supernus Pharmaceuticals reported revenues of US$211.3 million, a 27.7% year-on-year increase, and raised its full-year revenue and operating income guidance above analyst expectations, citing strong performance from growth products and effective commercial execution. This combination of outperformance and upgraded guidance suggests Supernus’s existing CNS portfolio is scaling efficiently, reinforcing management’s confidence in the company’s current commercial model. With...

Yahoo9/18/2026

Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Supernus Pharmaceuticals (NASDAQ:SUPN) and its peers.

Yahoo9/18/2026

3 Cash-Heavy Stocks Walking a Fine Line

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.

Yahoo9/16/2026

1 of Wall Street’s Favorite Stocks with Promising Prospects and 2 Facing Headwinds

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

Yahoo9/8/2026

Related Stocks (Peers)

Companies operating in similar sectors to SUPN:

ELVNTARSMBXLQDASUPNAMRXHRMYVRNO.NEPBHGPCRLLY

Recent Insider Transactions

DateNameShares ChangedPriceValue
2026-08-12Rubin Jonathan-750--
2026-08-12Rubin Jonathan-363$46.57$16,905
2026-08-12Rubin Jonathan+750--
2026-08-12Mottola Frank-1,650--
2026-08-12Mottola Frank-797$46.57$37,116
2026-08-12Mottola Frank+1,650--
2026-08-12Khattar Jack A.-29,849--
2026-08-12Khattar Jack A.-12,642$46.57$588,738
2026-08-12Khattar Jack A.+29,849--
2026-08-12Bhatt Padmanabh P.-2,500--
2026-08-12Bhatt Padmanabh P.-1,158$46.57$53,928
2026-08-12Bhatt Padmanabh P.+2,500--
2026-08-12DEC TIMOTHY C-1,250--
2026-08-12DEC TIMOTHY C-604$46.57$28,128
2026-08-12DEC TIMOTHY C+1,250--
2026-07-29Rubin Jonathan+750--
2026-07-29Mottola Frank+1,650--
2026-07-29Khattar Jack A.+29,849--
2026-07-29Bhatt Padmanabh P.+2,500--
2026-07-29DEC TIMOTHY C+1,250--
2026-03-18Bhatt Padmanabh P.-7,250--
2026-03-18Bhatt Padmanabh P.-412$50.48$20,798
2026-03-18Bhatt Padmanabh P.-6,838$49.55$338,823
2026-03-18Bhatt Padmanabh P.+7,250$39.4$285,650
2026-03-17Bhatt Padmanabh P.-15,000--
2026-03-17Bhatt Padmanabh P.-12,250--
2026-03-17Bhatt Padmanabh P.-22,750--
2026-03-17Bhatt Padmanabh P.-22,290$50.73$1,130,772
2026-03-17Bhatt Padmanabh P.-27,710$49.95$1,384,115
2026-03-17Bhatt Padmanabh P.+15,000$38.6$579,000
2026-03-17Bhatt Padmanabh P.+12,250$36.75$450,188
2026-03-17Bhatt Padmanabh P.+22,750$39.4$896,350
2026-03-16Bhatt Padmanabh P.-5,000--
2026-03-16Bhatt Padmanabh P.-18,000--
2026-03-16Bhatt Padmanabh P.-4,250--
2026-03-16Bhatt Padmanabh P.-22,750--
2026-03-16Bhatt Padmanabh P.-15,886$50.49$802,084
2026-03-16Bhatt Padmanabh P.-34,114$50.18$1,711,841
2026-03-16Bhatt Padmanabh P.+5,000$27.94$139,700
2026-03-16Bhatt Padmanabh P.+18,000$32.2$579,600
2026-03-16Bhatt Padmanabh P.+4,250$29.61$125,843
2026-03-16Bhatt Padmanabh P.+22,750$36.75$836,063
2026-03-13Khattar Jack A.-120$51.75$6,210
2026-03-13Khattar Jack A.-10,742$51$547,842
2026-03-13Khattar Jack A.-24,138$50.09$1,209,072
2026-03-13Khattar Jack A.-12,500--
2026-03-13Khattar Jack A.+12,500--
2026-03-12Hudson Frederick M.-5,369$50.61$271,725
2026-03-10Horich William Todd-4,439$55$244,145
2026-03-09Horich William Todd-4,438$54$239,652
2026-03-09Mottola Frank-1,623$53.65$87,074
2026-03-06Horich William Todd-1,125--
2026-03-06Horich William Todd-3,750--
2026-03-06Horich William Todd-2,625--
2026-03-06Horich William Todd-521$54.73$28,514
2026-03-06Horich William Todd+1,125--
2026-03-06Horich William Todd-1,718$54.73$94,026
2026-03-06Horich William Todd+3,750--
2026-03-06Horich William Todd-1,216$54.73$66,552
2026-03-06Horich William Todd+2,625--
2026-03-06Mottola Frank-3,750--
2026-03-06Mottola Frank-1,793$54.73$98,131
2026-03-06Mottola Frank+3,750--
2026-03-06Khattar Jack A.-38,640--
2026-03-06Khattar Jack A.-16,574$54.73$907,095
2026-03-06Khattar Jack A.+38,640--
2026-03-06DEC TIMOTHY C-3,000--
2026-03-06DEC TIMOTHY C-3,000--
2026-03-06DEC TIMOTHY C-1,450$54.73$79,359
2026-03-06DEC TIMOTHY C+3,000--
2026-03-06DEC TIMOTHY C-1,433$54.73$78,428
2026-03-06DEC TIMOTHY C+3,000--
2026-03-06GEMAYEL GEORGES-7,905--
2026-03-06GEMAYEL GEORGES-8,787$53$465,711
2026-03-06GEMAYEL GEORGES+7,905$25.3$199,997
2026-03-05GEMAYEL GEORGES-10,000$53.71$537,100
2026-02-28Mottola Frank+3,750--
2026-02-28Khattar Jack A.+38,640--
2026-02-28DEC TIMOTHY C+3,000--
2026-02-28DEC TIMOTHY C+3,000--
2026-02-25Rubin Jonathan-1,250--
2026-02-25Rubin Jonathan-675$50.69$34,216
2026-02-25Rubin Jonathan+1,250--
2026-02-25Mottola Frank-1,875--
2026-02-25Mottola Frank-977$50.69$49,524
2026-02-25Mottola Frank+1,875--
2026-02-25Bhatt Padmanabh P.-1,250--
2026-02-25Bhatt Padmanabh P.-650$50.69$32,949
2026-02-25Bhatt Padmanabh P.+1,250--
2026-02-25DEC TIMOTHY C-2,500--
2026-02-25DEC TIMOTHY C-1,279$50.69$64,833
2026-02-25DEC TIMOTHY C+2,500--
2026-02-24GEMAYEL GEORGES-4,475--
2026-02-24GEMAYEL GEORGES+4,475--
2026-02-24Rubin Jonathan-1,250--
2026-02-24Rubin Jonathan-750--
2026-02-24Rubin Jonathan-1,125--
2026-02-24Rubin Jonathan-671--
2026-02-24Rubin Jonathan+1,250--
2026-02-24Rubin Jonathan-369$50.86$18,767
2026-02-24Rubin Jonathan+750--
2026-02-24Rubin Jonathan-603$51.35$30,964
2026-02-24Rubin Jonathan+1,125--
2026-02-24Mottola Frank-1,250--
2026-02-24Mottola Frank-750--
2026-02-24Mottola Frank-1,125--
2026-02-24Mottola Frank-670$50.86$34,076
2026-02-24Mottola Frank+1,250--
2026-02-24Mottola Frank-368$50.86$18,716
2026-02-24Mottola Frank+750--
2026-02-24Mottola Frank-603$51.35$30,964
2026-02-24Mottola Frank+1,125--
2026-02-24Barlow Carrolee-4,475--
2026-02-24Barlow Carrolee+4,475--
2026-02-24Bhatt Padmanabh P.-1,250--
2026-02-24Bhatt Padmanabh P.-750--
2026-02-24Bhatt Padmanabh P.-1,125--
2026-02-24Bhatt Padmanabh P.-646$50.86$32,856
2026-02-24Bhatt Padmanabh P.+1,250--
2026-02-24Bhatt Padmanabh P.-354$50.86$18,004
2026-02-24Bhatt Padmanabh P.+750--
2026-02-24Bhatt Padmanabh P.-581$51.35$29,834
2026-02-24Bhatt Padmanabh P.+1,125--
2026-02-24Hudson Frederick M.-4,475--
2026-02-24Hudson Frederick M.+4,475--
2026-02-24DEC TIMOTHY C-3,000--
2026-02-24DEC TIMOTHY C-500--
2026-02-24DEC TIMOTHY C-1,125--
2026-02-24DEC TIMOTHY C-1,524$50.86$77,511
2026-02-24DEC TIMOTHY C+3,000--
2026-02-24DEC TIMOTHY C-242$50.86$12,308
2026-02-24DEC TIMOTHY C+500--
2026-02-24DEC TIMOTHY C-603$51.35$30,964
2026-02-24DEC TIMOTHY C+1,125--
2026-02-24NEWHALL CHARLES W III-4,475--
2026-02-24NEWHALL CHARLES W III+4,475--
2026-02-23GEMAYEL GEORGES-15,000--
2026-02-23GEMAYEL GEORGES+15,000$12.98$194,700
2026-02-19Sensenig Bethany-4,475--
2026-02-19Sensenig Bethany-3,258$51.27$167,038
2026-02-19Sensenig Bethany-1,217$50.31$61,227
2026-02-19Sensenig Bethany+4,475--
2026-02-18Sensenig Bethany+4,977--
2026-02-18Sensenig Bethany+2,989--
2026-02-18Rubin Jonathan+3,000--
2026-02-18Rubin Jonathan+13,500--
2026-02-18Mottola Frank+3,000--
2026-02-18Mottola Frank+13,500--
2026-02-18Barlow Carrolee+4,977--
2026-02-18Barlow Carrolee+2,989--
2026-02-18Khattar Jack A.+341,610--
2026-02-18Bhatt Padmanabh P.+3,000--
2026-02-18Bhatt Padmanabh P.+13,500--
2026-02-18Hudson Frederick M.+4,977--
2026-02-18Hudson Frederick M.+2,989--
2026-02-18GEMAYEL GEORGES+4,977--
2026-02-18GEMAYEL GEORGES+2,989--
2026-02-18DEC TIMOTHY C+3,000--
2026-02-18DEC TIMOTHY C+17,500--
2026-02-18NEWHALL CHARLES W III+4,977--
2026-02-18NEWHALL CHARLES W III+2,989--
2026-01-09Hudson Frederick M.-15,000--
2026-01-09Hudson Frederick M.+15,000$12.98$194,700
2025-12-19Mottola Frank-15,000--
2025-12-19Mottola Frank-5,000--
2025-12-19Mottola Frank-15,000$50.47$757,050
2025-12-19Mottola Frank+15,000$25.3$379,500
2025-12-19Mottola Frank-5,000$50.22$251,100
2025-12-19Mottola Frank+5,000$39.4$197,000
2025-12-18Bhatt Padmanabh P.-1,500--
2025-12-18Bhatt Padmanabh P.-710$44.44$31,552
2025-12-18Bhatt Padmanabh P.+1,500--
2025-11-21NEWHALL CHARLES W III-15,000--
2025-11-21NEWHALL CHARLES W III+15,000$12.98$194,700
2025-11-13Bhatt Padmanabh P.+1,500--
2025-10-09Khattar Jack A.-81,250--
2025-10-09Khattar Jack A.-1,529$51.46$78,682
2025-10-09Khattar Jack A.-58,371$50.55$2,950,654
2025-10-09Khattar Jack A.+81,250$25.3$2,055,625
2025-10-09NEWHALL CHARLES W III-1,200$51.55$61,860
2025-10-09NEWHALL CHARLES W III-23,800$50.73$1,207,374